Company intelligence / Profile preview

Animal Biosciences

Boston, Massachusetts, United Statesanimbiosci.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Animal Biosciences has developed the Leap Years Cellular Longevity System for Dogs, a chewable supplement shown in a double-blind clinical trial at North Carolina State University to reverse age-related decline in dogs. The study demonstrated improvements in cognition, frailty, and engagement among senior dogs. The company is also developing additional small molecule therapies targeting aging and age-related diseases in companion animals[9].

Therapeutic areas: OtherNeurology
Modalities: Small moleculeSupplement
Industry: Veterinary

Drug pipeline

1 asset

Leap Years

Pre-clinical

Indications: Age-related conditions in dogs

Partnerships

DinbeatNorth Carolina State University College of Veterinary Medicine

Beyond the preview

Go deeper on Animal Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Animal Biosciences.

Explore the full profile